Results 1 to 10 of about 3,349,315 (392)

Acknowledgment to Reviewers of Biologics in 2021

Biologics, 2022
Rigorous peer-reviews are the basis of high-quality academic publishing [...]
Biologics Editorial Office
doaj   +1 more source

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

OncoImmunology, 2021
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it.
Haiping Jiang, Haiqing Ni, Pan Zhang, Xiaoli Guo, Min Wu, Haoran Shen, Jie Wang, Weiwei Wu, Zhihai Wu, Jiazheng Ding, Rong Tang, Shuaixiang Zhou, Bingliang Chen, Michael Yu, Hua Jing, Junjian Liu   +15 more
doaj   +1 more source

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

Nature Communications, 2021
The toxicity arising from generalised stimulation of T cells restricts applicability of CD137 agonists in cancer immune therapy. Here authors show that a bispecific antibody blocking PD-1 while activating CD137 efficiently restricts T cell activation to ...
Yunqian Qiao, Yangmin Qiu, Jie Ding, Nana Luo, Hao Wang, Xiaomin Ling, Jiya Sun, Zhihai Wu, Yisen Wang, Yanpeng Liu, Feifei Guo, Ta Sun, Wanwan Shen, Min Zhang, Dongdong Wu, Bingliang Chen, Wei Xu, Xuan Wang   +17 more
doaj   +1 more source

Development of a stable antibody production system utilizing an Hspa5 promoter in CHO cells

Scientific Reports, 2022
Chinese hamster ovary (CHO) cells are widely used for manufacturing antibody drugs. We attempted to clone a novel high-expression promoter for producing monoclonal antibodies (mAbs) based on transcriptome analysis to enhance the transcriptional abundance
Hiroki Tanemura, Kenji Masuda, Takeshi Okumura, Eri Takagi, Daisuke Kajihara, Hirofumi Kakihara, Koichi Nonaka, Ryo Ushioda   +7 more
doaj   +1 more source

Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine

Scientific Reports, 2022
Intramuscular vaccines have greatly reduced hospitalization and death due to severe COVID-19. However, most countries are experiencing a resurgence of infection driven predominantly by the Delta and Omicron variants of SARS-CoV-2.
Yi-Jiun Lin, Meei-Yun Lin, Ya-Shan Chuang, Luke Tzu-Chi Liu, Tsun-Yung Kuo, Charles Chen, Shyamala Ganesan, Ali Fattom, Vira Bitko, Chia-En Lien   +9 more
doaj   +1 more source

The Future of Generic Biologics: Should the United States “Follow-On” the European Pathway? [PDF]

, 2008
The United States is embarking on a biotechnology drug revolution. In the last few decades, biotech drugs have saved millions of lives, and the market for these miracle cures continues to grow at an astronomical rate.
Kaldre, Ingrid
core   +4 more sources

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques

Emerging Microbes and Infections, 2022
Mucosal immunity provides a potential for preventing initial infection and stopping subsequent transmission of SARS-CoV-2. Here, we examined the safety and immunogenicity of a replication-defective adenovirus type-5 vectored vaccine (Ad5-nCov) encoding ...
Fang Xu, Shipo Wu, Linan Yi, Shaodan Peng, Fan Wang, Weixue Si, Lihua Hou, Tao Zhu   +7 more
doaj   +1 more source

Taking Biologics for Granted? Takings, Trade Secrets, and Off-Patent Biological Products [PDF]

, 2005
Biologics are complex medicines which are often genetically engineered, and which are sure to play an important role in curing some of humankind\u27s worst diseases. Not surprisingly, generic companies want a part of the biologic market. The FDA believes
Bergman, Karl-Olof, Milberg, Per, Wikstroem, Linnea   +2 more
core   +3 more sources

Strategies for Targeted Delivery of Exosomes to the Brain: Advantages and Challenges

Pharmaceutics, 2022
Delivering therapeutics to the central nervous system (CNS) is difficult because of the blood–brain barrier (BBB). Therapeutic delivery across the tight junctions of the BBB can be achieved through various endogenous transportation mechanisms.
Hojun Choi, Kyungsun Choi, Dae-Hwan Kim, Byung-Koo Oh, Hwayoung Yim, Soojin Jo, Chulhee Choi   +6 more
doaj   +1 more source

A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope

mAbs, 2020
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CD152) is a receptor on T cells that inhibits the cell’s functions. Blocking CTLA-4 with an antibody has proven effective for the treatment of cancer patients. Anti-CTLA-4 antibodies currently approved
Dong Li, Jing Li, Huanyu Chu, Zhuozhi Wang   +3 more
doaj   +1 more source